Dr. Hackworth is a pharmaceutical executive with an extensive track record in licensing, M&A, and partnership transactions, particularly ones with a high degree of complexity, pharmaceutical commercialization and clinical development strategy and is an expert on the US pain market. He began his career in strategy consulting with McKinsey and Company and recently served as Senior Vice President of Corporate Development and Commercialization Strategy at Shionogi, Inc. He helped Shionogi remake its US business through a series of transactions over several years and the commercial strategy and execution for launching several drugs generated from its pipeline. Currently, in addition to Park, Dr Hackworth is a Mid-Atlantic Bio-Angles Steering Committee member and a Board member for Elysium Therapeutics. He graduated summa cum laude with a BS in physics from the Ohio State University in 1998 and a PhD in theoretical physics from Columbia University in 2006.
Speaking In
[Available On-Demand]
Park Therapeutics is a private company that was formed to address the desperate need for better and…